SOAM
RVMD icon

SBI Okasan Asset Management’s Revolution Medicines RVMD Stock Holding History

SBI Okasan Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Hold
9,900
– – 0.06% 57
2026
Q1 		$918K Hold
9,900
– – 0.04% 117
2025
Q4 		$797K Buy
+9,900
New +$649K 0.04% 137

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

SBI Okasan Asset Management's RVMD Position: Q2 2026 in Review

SBI Okasan Asset Management held its Revolution Medicines (RVMD) position steady in Q2 2026 at 9,900 shares worth $1.91M. The position accounts for 0.06% of the portfolio, ranked #57.

SBI Okasan Asset Management first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • SBI Okasan Asset Management held 9,900 shares of Revolution Medicines worth $1.91M as of Q2 2026.
  • SBI Okasan Asset Management left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 0.06% of SBI Okasan Asset Management's portfolio in Q2 2026, its #57 holding.
  • SBI Okasan Asset Management first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.